CHARTING THE PATH TO
Magellan Bioanalytics applies proprietary AI software to find serum biomarkers that can improve precision medicine. Our proprietary technology has successfully identified biomarkers that predict or stage disease in various indications, from breast cancer to Alzheimer's.
Magellan analyzes levels of small biomolecule products deposited into the serum from all ongoing cellular processes across the body. Those products represent >120,000 potential biomarkers that directly reflect the current health of the individual.
Our internal research centers on developing a biomarker database of cancer patients, with a goal of guiding oncologic treatment.
Additionally, we form partnerships to develop precision medicine solutions for other areas of human health.